Shared genetic risk factors: implications for treatment of idiopathic pulmonary fibrosis and systemic hypertension.

Gina Parcesepe, Richard J Allen, Beatriz Guillen-Guio, Samuel Moss, R Gisli Jenkins, Louise V Wain

Abstract read

In one paragraph

Article in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Nedd4L-mediated stabilization of morphogenetic protein receptor 2 in lung fibroblasts confers protection against pulmonary fibrosis.Signal transduction and targeted therapy · 2026
Article
Tailored Exercise Prescription for People with COPD and Clinically Relevant Comorbidities: A Consensus Statement of the EXPERT Working Group and Experts in Pulmonary Rehabilitation.Sports medicine (Auckland, N.Z.) · 2026
Review
Genome-wide assessment of shared genetic landscape of idiopathic pulmonary fibrosis and its comorbidities.Human genetics · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gina ParcesepeDepartment of Population Health Sciences, University of Leicester, Leicester, UK.ORCID https://orcid.org/0009-0004-8494-6780

Richard J AllenDepartment of Population Health Sciences, University of Leicester, Leicester, UK.

Beatriz Guillen-GuioDepartment of Population Health Sciences, University of Leicester, Leicester, UK.

Samuel MossMargaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK.

R Gisli JenkinsMargaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK.

Louise V WainDepartment of Population Health Sciences, University of Leicester, Leicester, UK.

Funding

Medical Research Council MR/V005324/1Medical Research Council MR/W014491/1Wellcome Trust

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37965228

DOI10.1183/23120541.00457-2023

PMCPMC10641590

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.